Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience executive Dennis Cho reported a routine tax-related stock sale. On February 3, 2026, he sold 1,099 shares of Twist Bioscience common stock at $46.576 per share to cover tax withholding from vesting restricted stock units under the company’s equity plans.
After this mandated “sell to cover” transaction, Cho beneficially owned 143,581 shares of common stock in direct ownership. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and the filing notes these were not discretionary trades.
Twist Bioscience Corp’s Chief Executive Officer and director Emily M. Leproust reported an automatic sale of common stock tied to equity compensation. On February 3, 2026, she sold 5,001 shares of common stock at $46.576 per share in a transaction coded “S.”
The filing explains these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, described as a mandatory “sell to cover” and not a discretionary trade. After this sale, Leproust beneficially owned 869,312 shares of Twist Bioscience common stock and continued to hold various employee stock options, including 64,950 performance stock options that vested after meeting performance criteria in December 2022.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported mandatory sales of common stock to cover taxes on vested restricted stock units. On February 3, 2026, he sold 175 shares at $46.576 per share. On February 4, 2026, he sold an additional 7,000 shares at a weighted average price of $45.648 per share, with actual sale prices ranging from $45.61 to $45.78. These "sell to cover" transactions were required under the company’s equity incentive plan and are described as non-discretionary. After these transactions, Werner directly owned 58,738 shares of Twist Bioscience common stock.
Twist Bioscience Corporation reported that SVP of Human Resources Paula Green sold 1,194 shares of common stock on February 3, 2026 at $46.576 per share. After this transaction, she directly holds 165,445 shares.
The sale was a mandatory “sell to cover” transaction to satisfy tax withholding owed on vesting restricted stock units, under the company’s equity incentive plan, and was not a discretionary trade by the executive.
Robert F. Werner has filed a notice of proposed sale of 7,000 common shares, with an aggregate market value of $319,532.51, to be sold through Fidelity Brokerage Services LLC on NASDAQ around 02/04/2026. The filing lists 61,311,704 common shares outstanding.
The 7,000 shares come from restricted stock that vested as compensation between 05/22/2024 and 02/02/2025, in multiple smaller tranches. The notice also reports past three-month sales by Werner totaling 1,456 shares across four transactions, with disclosed gross proceeds for each sale.
Patrick Finn has filed notice to sell 2,705 shares of common stock of TWST on or about 02/03/2026 through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $125,986.73.
The shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Finn reported several sales of TWST common stock, including 23,279 shares on 01/13/2026 for $931,160.00 and 2,390 shares on 01/23/2026 for $107,329.41.
A shareholder of TWST has filed a Rule 144 notice to sell 175 shares of common stock on the NASDAQ through Fidelity Brokerage Services, with an approximate sale date of February 3, 2026.
The 175 shares were acquired on February 2, 2026 through restricted stock vesting from the issuer as compensation. The filing also lists recent sales for the same seller, including 160 common shares sold on November 3, 2025 for $5,132.70 and 822 common shares sold on November 24, 2025 for $23,599.21. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
TWST shareholder Paula Green filed a Rule 144 notice to sell 1,194 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $55,611.15, when 61,311,704 shares were outstanding and the approximate sale date listed as 02/03/2026.
The shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Green reported four separate common stock sales between 11/03/2025 and 12/22/2025. By signing, she represents she is not aware of undisclosed material adverse information about the issuer.
Twist Bioscience insider plans to sell common stock under Rule 144. Dennis H. Cho filed a notice to sell 1,099 common shares through Fidelity Brokerage Services on NASDAQ around 02/03/2026, with an aggregate market value of $51,186.47. The issuer has 61,311,704 common shares outstanding.
The 1,099 shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Cho has sold additional common shares: 1,019 shares for $32,688.91 on 11/03/2025, 757 shares for $20,063.15 on 11/21/2025, 398 shares for $13,085.28 on 12/08/2025, and 324 shares for $11,196.14 on 12/22/2025.
An insider of the company trading under symbol TWST has filed a Rule 144 notice to sell 5,001 shares of common stock through Fidelity Brokerage Services LLC on or about 02/03/2026 on the NASDAQ, with an aggregate market value listed as $232,924.08.
The 5,001 shares were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. The filer also reports prior sales in the last three months, including 4,887 common shares sold on 11/03/2025 for gross proceeds of $156,772.03. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.